Found 353 articles
Mesoblast shares dropped on the last day of August 2021 after it was told that its candidate COVID-19 treatment needs to undergo another trial to be green-lit for emergency approval by the FDA.
Brickell Biotech, Inc. today announced that it has appointed Monica Luchi, MD, FACR, MBA to the newly created role of Chief Medical Officer.
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the fourth quarter and full-year ended June 30, 2021 (FY2021).
Acute Graft Versus Host Disease [GvHD] Treatment Market: Intravenous Segment to Expand at High Growth Rate
According to the report, the global acute graft versus host disease treatment market was valued at US$ 263 Mn in 2020 and is projected to expand at a CAGR of 8.6% from 2021 to 2031.
Regenerative medicine has made extensive advancements over the years to cure the populace of certain disorders or diseases.
New therapeutic modalities always face an uphill climb, but the urgency of COVID-19 may have opened the door for two related ones: cell therapies and exosomes.
Imvax Further Strengthens Leadership Team with Appointment of Josh Muntner as Chief Financial Officer
Imvax announced the appointment of Josh Muntner as the company’s chief financial officer effective August 31, 2021.
Cellular Reprogramming Tools Market: Innovative Competitive Strategies of Key Players Fueling Market Growth
Cell reprogramming is reverting mature, specialized cells into induced pluripotent stem cells and re-establishing epigenetic marks during mammalian germ cell development.
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, provided an update on its pipeline of late-stage product candidates, and an activity report for the fourth quarter ended June 30, 2021.
7/26/2021It was another busy week for clinical trial updates. Here’s a look at some including Mesoblast Limited, CytoDyn, Magenta Therapeutics and more.
7/19/2021It was a moderately busy mid-summer week for clinical trial news. Here’s a look.
Ninety Day Survival Outcomes in COVID-19 ARDS Trial of Remestemcel-L Presented at ISCT Meeting on Advances in Cell & Gene Therapies for Lung Diseases
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, presented 90-day survival outcomes from the 222-patient randomized controlled trial of remestemcel-L in ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome at an invited presentation on July 17 to the International Society for Cell & Gene Therapy Scientific Signatures Series on Cell and Gene Therapies in Lung Diseases and Critical Illnesses.
Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, presented clinical outcomes from the randomized controlled trial of remestemcel-L in ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome.
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the strategy for bringing rexlemestrocel-L to patients in the United States (US) with chronic low back pain (CLBP) due to degenerative disc disease (DDD) refractory to available therapies, including opioids.
Medexus Pharmaceuticals Inc. announced that it has expanded its medical affairs team in preparation for the planned launch of treosulfan, a bifunctional alkylating agent, in the United States.
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, reported operational highlights and financial results for the period ended March 31, 2021.
Stem Cell Therapy Market Increasing Awareness Related to the Stem Cells Therapy in Effective Disease Management
The global stem cell therapy market is expected to reach US$ 5,129.66 Mn in 2027 from US$ 1,534.55 Mn in 2019.
Improved Outcomes in Inflammatory Lung Disease With Remestemcel-L Published in Respiratory Research Journal
Mesoblast Limited announced that the peer-reviewed journal Respiratory Research has published results showing that Mesoblast’s mesenchymal stromal cell product candidate remestemcel-L significantly improved respiratory and functional clinical outcomes in patients with chronic obstructive pulmonary disease and elevated levels of the inflammatory biomarker C-reactive protein.
MANA Therapeutics, a clinical-stage company creating nonengineered, off-the-shelf allogeneic cell therapies that target multiple cancer antigens, today announced the appointment of Arthur (Andy) Hurwitz, Ph.D., t
Appendix 4C Quarterly Activity ReportMesoblast Operational and Financial Highlights for Quarter Ended March 31, 2021
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, provided an update on its pipeline of late-stage product candidates, and an activity report for the third quarter ended March 31, 2021.